EP3510052A1 - Method for preparing an extract of hevea latex and composition thereof - Google Patents
Method for preparing an extract of hevea latex and composition thereofInfo
- Publication number
- EP3510052A1 EP3510052A1 EP16915342.6A EP16915342A EP3510052A1 EP 3510052 A1 EP3510052 A1 EP 3510052A1 EP 16915342 A EP16915342 A EP 16915342A EP 3510052 A1 EP3510052 A1 EP 3510052A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cancer
- extract
- hevea latex
- cell
- hevea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000126 latex Polymers 0.000 title claims abstract description 118
- 239000004816 latex Substances 0.000 title claims abstract description 118
- 229920003211 cis-1,4-polyisoprene Polymers 0.000 title claims abstract description 116
- 239000000284 extract Substances 0.000 title claims abstract description 105
- 238000000034 method Methods 0.000 title claims abstract description 78
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 241000221020 Hevea Species 0.000 title claims abstract 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 39
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 39
- 210000002966 serum Anatomy 0.000 claims abstract description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000002253 acid Substances 0.000 claims abstract description 22
- 206010027476 Metastases Diseases 0.000 claims abstract description 15
- 230000009401 metastasis Effects 0.000 claims abstract description 15
- 239000002244 precipitate Substances 0.000 claims abstract description 15
- 239000000843 powder Substances 0.000 claims abstract description 14
- 239000007787 solid Substances 0.000 claims abstract description 14
- DSCFFEYYQKSRSV-FIZWYUIZSA-N (-)-Quebrachitol Chemical compound CO[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@H]1O DSCFFEYYQKSRSV-FIZWYUIZSA-N 0.000 claims abstract description 11
- DSCFFEYYQKSRSV-UHFFFAOYSA-N 1L-O1-methyl-muco-inositol Natural products COC1C(O)C(O)C(O)C(O)C1O DSCFFEYYQKSRSV-UHFFFAOYSA-N 0.000 claims abstract description 11
- 239000002904 solvent Substances 0.000 claims abstract description 11
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 238000003490 calendering Methods 0.000 claims abstract description 10
- 244000005700 microbiome Species 0.000 claims abstract description 10
- 230000001376 precipitating effect Effects 0.000 claims abstract description 8
- 238000004108 freeze drying Methods 0.000 claims abstract description 5
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 5
- 230000005907 cancer growth Effects 0.000 claims abstract description 4
- 230000004663 cell proliferation Effects 0.000 claims abstract description 4
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 4
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 100
- 201000011510 cancer Diseases 0.000 claims description 70
- 210000004027 cell Anatomy 0.000 claims description 35
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 24
- 239000003550 marker Substances 0.000 claims description 17
- 238000001694 spray drying Methods 0.000 claims description 17
- 238000000108 ultra-filtration Methods 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 14
- 201000001441 melanoma Diseases 0.000 claims description 12
- 238000001556 precipitation Methods 0.000 claims description 12
- 210000003491 skin Anatomy 0.000 claims description 11
- 102000000802 Galectin 3 Human genes 0.000 claims description 10
- 108010001517 Galectin 3 Proteins 0.000 claims description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 230000006907 apoptotic process Effects 0.000 claims description 9
- 239000012528 membrane Substances 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 210000004072 lung Anatomy 0.000 claims description 8
- 230000035755 proliferation Effects 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 7
- 210000003734 kidney Anatomy 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 7
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 7
- 206010039491 Sarcoma Diseases 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 6
- 210000002889 endothelial cell Anatomy 0.000 claims description 6
- 210000004185 liver Anatomy 0.000 claims description 6
- 201000005962 mycosis fungoides Diseases 0.000 claims description 6
- 239000011148 porous material Substances 0.000 claims description 6
- 206010003571 Astrocytoma Diseases 0.000 claims description 5
- 241000282414 Homo sapiens Species 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 claims description 5
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 claims description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- 230000034994 death Effects 0.000 claims description 5
- 231100000517 death Toxicity 0.000 claims description 5
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 5
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 239000004615 ingredient Substances 0.000 claims description 5
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 5
- 210000002307 prostate Anatomy 0.000 claims description 5
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 claims description 4
- 201000000582 Retinoblastoma Diseases 0.000 claims description 4
- 208000021712 Soft tissue sarcoma Diseases 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 4
- 230000000996 additive effect Effects 0.000 claims description 4
- 230000002491 angiogenic effect Effects 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 208000002458 carcinoid tumor Diseases 0.000 claims description 4
- 239000002771 cell marker Substances 0.000 claims description 4
- 229940127089 cytotoxic agent Drugs 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 210000001508 eye Anatomy 0.000 claims description 4
- 230000002349 favourable effect Effects 0.000 claims description 4
- 239000000945 filler Substances 0.000 claims description 4
- 239000000314 lubricant Substances 0.000 claims description 4
- 210000000214 mouth Anatomy 0.000 claims description 4
- 201000002575 ocular melanoma Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- 210000001550 testis Anatomy 0.000 claims description 4
- 206010044412 transitional cell carcinoma Diseases 0.000 claims description 4
- 241000701806 Human papillomavirus Species 0.000 claims description 3
- -1 carrier Substances 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 208000005017 glioblastoma Diseases 0.000 claims description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- 230000003211 malignant effect Effects 0.000 claims description 3
- 210000000496 pancreas Anatomy 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 210000002784 stomach Anatomy 0.000 claims description 3
- 210000003932 urinary bladder Anatomy 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 2
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims description 2
- 201000004384 Alopecia Diseases 0.000 claims description 2
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 claims description 2
- 201000003076 Angiosarcoma Diseases 0.000 claims description 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims description 2
- 229940122815 Aromatase inhibitor Drugs 0.000 claims description 2
- 206010003594 Ataxia telangiectasia Diseases 0.000 claims description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
- 206010004272 Benign hydatidiform mole Diseases 0.000 claims description 2
- 206010004593 Bile duct cancer Diseases 0.000 claims description 2
- 206010006143 Brain stem glioma Diseases 0.000 claims description 2
- 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
- 208000006332 Choriocarcinoma Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010053138 Congenital aplastic anaemia Diseases 0.000 claims description 2
- 206010052465 Congenital poikiloderma Diseases 0.000 claims description 2
- 208000008334 Dermatofibrosarcoma Diseases 0.000 claims description 2
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 claims description 2
- 208000006402 Ductal Carcinoma Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 2
- 206010014967 Ependymoma Diseases 0.000 claims description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
- 201000001342 Fallopian tube cancer Diseases 0.000 claims description 2
- 208000013452 Fallopian tube neoplasm Diseases 0.000 claims description 2
- 201000004939 Fanconi anemia Diseases 0.000 claims description 2
- 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 claims description 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 2
- 208000033640 Hereditary breast cancer Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000006937 Hydatidiform mole Diseases 0.000 claims description 2
- 206010061252 Intraocular melanoma Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 201000005099 Langerhans cell histiocytosis Diseases 0.000 claims description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 claims description 2
- 201000011062 Li-Fraumeni syndrome Diseases 0.000 claims description 2
- 206010025282 Lymphoedema Diseases 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000004059 Male Breast Neoplasms Diseases 0.000 claims description 2
- 208000032271 Malignant tumor of penis Diseases 0.000 claims description 2
- 208000000172 Medulloblastoma Diseases 0.000 claims description 2
- 208000002030 Merkel cell carcinoma Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 229940121849 Mitotic inhibitor Drugs 0.000 claims description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 208000009905 Neurofibromatoses Diseases 0.000 claims description 2
- 208000004485 Nijmegen breakage syndrome Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 206010057444 Oropharyngeal neoplasm Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 208000000821 Parathyroid Neoplasms Diseases 0.000 claims description 2
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 2
- 206010034299 Penile cancer Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 208000000791 Rothmund-Thomson syndrome Diseases 0.000 claims description 2
- 208000009359 Sezary Syndrome Diseases 0.000 claims description 2
- 208000021388 Sezary disease Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims description 2
- 102000012349 Uroplakins Human genes 0.000 claims description 2
- 108010061861 Uroplakins Proteins 0.000 claims description 2
- 201000005969 Uveal melanoma Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 208000008383 Wilms tumor Diseases 0.000 claims description 2
- 208000017733 acquired polycythemia vera Diseases 0.000 claims description 2
- 208000002517 adenoid cystic carcinoma Diseases 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 231100000360 alopecia Toxicity 0.000 claims description 2
- 208000008524 alveolar soft part sarcoma Diseases 0.000 claims description 2
- 230000000340 anti-metabolite Effects 0.000 claims description 2
- 239000002518 antifoaming agent Substances 0.000 claims description 2
- 229940100197 antimetabolite Drugs 0.000 claims description 2
- 239000002256 antimetabolite Substances 0.000 claims description 2
- 239000003972 antineoplastic antibiotic Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 239000003886 aromatase inhibitor Substances 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 208000011654 childhood malignant neoplasm Diseases 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 2
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 210000003372 endocrine gland Anatomy 0.000 claims description 2
- 201000004101 esophageal cancer Diseases 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 201000008819 extrahepatic bile duct carcinoma Diseases 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 235000010037 flour treatment agent Nutrition 0.000 claims description 2
- 235000002864 food coloring agent Nutrition 0.000 claims description 2
- 235000019264 food flavour enhancer Nutrition 0.000 claims description 2
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 210000000232 gallbladder Anatomy 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 230000002496 gastric effect Effects 0.000 claims description 2
- 208000003884 gestational trophoblastic disease Diseases 0.000 claims description 2
- 201000007116 gestational trophoblastic neoplasm Diseases 0.000 claims description 2
- 210000003128 head Anatomy 0.000 claims description 2
- 208000025581 hereditary breast carcinoma Diseases 0.000 claims description 2
- 201000008298 histiocytosis Diseases 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000003652 hormone inhibitor Substances 0.000 claims description 2
- 239000003906 humectant Substances 0.000 claims description 2
- 201000006866 hypopharynx cancer Diseases 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 208000022013 kidney Wilms tumor Diseases 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims description 2
- 210000000867 larynx Anatomy 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 210000000088 lip Anatomy 0.000 claims description 2
- 206010024627 liposarcoma Diseases 0.000 claims description 2
- 208000014018 liver neoplasm Diseases 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 208000002502 lymphedema Diseases 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims description 2
- 201000003175 male breast cancer Diseases 0.000 claims description 2
- 208000010907 male breast carcinoma Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 208000026045 malignant tumor of parathyroid gland Diseases 0.000 claims description 2
- 208000037819 metastatic cancer Diseases 0.000 claims description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims description 2
- 206010051747 multiple endocrine neoplasia Diseases 0.000 claims description 2
- 206010028537 myelofibrosis Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 210000003928 nasal cavity Anatomy 0.000 claims description 2
- 210000003739 neck Anatomy 0.000 claims description 2
- 201000008026 nephroblastoma Diseases 0.000 claims description 2
- 208000007538 neurilemmoma Diseases 0.000 claims description 2
- 201000004931 neurofibromatosis Diseases 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 210000001331 nose Anatomy 0.000 claims description 2
- 201000008106 ocular cancer Diseases 0.000 claims description 2
- 201000005443 oral cavity cancer Diseases 0.000 claims description 2
- 201000006958 oropharynx cancer Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 201000001219 parotid gland cancer Diseases 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 210000003800 pharynx Anatomy 0.000 claims description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
- 230000001817 pituitary effect Effects 0.000 claims description 2
- 208000037244 polycythemia vera Diseases 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- 230000002335 preservative effect Effects 0.000 claims description 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000003476 primary myelofibrosis Diseases 0.000 claims description 2
- 210000000664 rectum Anatomy 0.000 claims description 2
- 201000006402 rhabdoid cancer Diseases 0.000 claims description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
- 210000003079 salivary gland Anatomy 0.000 claims description 2
- 206010039667 schwannoma Diseases 0.000 claims description 2
- 201000008261 skin carcinoma Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000002314 small intestine cancer Diseases 0.000 claims description 2
- 210000000278 spinal cord Anatomy 0.000 claims description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 206010042863 synovial sarcoma Diseases 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002562 thickening agent Substances 0.000 claims description 2
- 210000001541 thymus gland Anatomy 0.000 claims description 2
- 210000001685 thyroid gland Anatomy 0.000 claims description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 2
- 208000029387 trophoblastic neoplasm Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 210000003708 urethra Anatomy 0.000 claims description 2
- 230000002485 urinary effect Effects 0.000 claims description 2
- 208000037965 uterine sarcoma Diseases 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 210000001215 vagina Anatomy 0.000 claims description 2
- 210000003905 vulva Anatomy 0.000 claims description 2
- 238000010306 acid treatment Methods 0.000 claims 3
- 208000007860 Anus Neoplasms Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 230000006920 protein precipitation Effects 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 abstract description 36
- 235000014633 carbohydrates Nutrition 0.000 abstract description 33
- 230000001093 anti-cancer Effects 0.000 abstract description 28
- 235000013376 functional food Nutrition 0.000 abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 5
- 244000043261 Hevea brasiliensis Species 0.000 description 107
- 235000018102 proteins Nutrition 0.000 description 33
- 239000007943 implant Substances 0.000 description 19
- 238000011580 nude mouse model Methods 0.000 description 18
- 241000699660 Mus musculus Species 0.000 description 16
- 230000037396 body weight Effects 0.000 description 16
- 230000033115 angiogenesis Effects 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 230000002001 anti-metastasis Effects 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 238000003364 immunohistochemistry Methods 0.000 description 9
- 239000007858 starting material Substances 0.000 description 9
- 239000012467 final product Substances 0.000 description 8
- 238000003305 oral gavage Methods 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 239000013566 allergen Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 210000003462 vein Anatomy 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 239000001814 pectin Substances 0.000 description 6
- 229920001277 pectin Polymers 0.000 description 6
- 235000010987 pectin Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 5
- 229920006173 natural rubber latex Polymers 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 210000001835 viscera Anatomy 0.000 description 5
- 238000012800 visualization Methods 0.000 description 5
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 230000002009 allergenic effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 229920001971 elastomer Polymers 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000220225 Malus Species 0.000 description 3
- 235000011430 Malus pumila Nutrition 0.000 description 3
- 235000015103 Malus silvestris Nutrition 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000005534 hematocrit Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000003808 methanol extraction Methods 0.000 description 3
- 238000003801 milling Methods 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 231100000456 subacute toxicity Toxicity 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 238000011729 BALB/c nude mouse Methods 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 2
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 2
- AHCYMLUZIRLXAA-SHYZEUOFSA-N Deoxyuridine 5'-triphosphate Chemical class O1[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 AHCYMLUZIRLXAA-SHYZEUOFSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical compound CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 231100000229 OECD 452 Chronic Toxicity Study Toxicity 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000001028 anti-proliverative effect Effects 0.000 description 2
- 239000002842 anticancer formulation Substances 0.000 description 2
- 239000002257 antimetastatic agent Substances 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000002306 biochemical method Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000004820 blood count Methods 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 231100000160 chronic toxicity Toxicity 0.000 description 2
- 230000007665 chronic toxicity Effects 0.000 description 2
- 235000020971 citrus fruits Nutrition 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229930004069 diterpene Natural products 0.000 description 2
- 150000004141 diterpene derivatives Chemical class 0.000 description 2
- 230000000437 effect on angiogenesis Effects 0.000 description 2
- 210000000918 epididymis Anatomy 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 230000008376 long-term health Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000004789 organ system Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000011076 safety test Methods 0.000 description 2
- 210000001625 seminal vesicle Anatomy 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 201000010653 vesiculitis Diseases 0.000 description 2
- 238000010865 video microscopy Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- JHORJRSRQZDYPZ-UHFFFAOYSA-N 1,1,4,7,9-pentamethyldodecahydro-1h-2,8a-methanocyclopenta[a]cyclopropa[e][10]annulene Chemical class CC1CC2C(C)(C)C2C2CC(C)CC3CC(C)CC31C2 JHORJRSRQZDYPZ-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical class OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 102100024025 Heparanase Human genes 0.000 description 1
- 229940122588 Heparanase inhibitor Drugs 0.000 description 1
- 101800002189 Hevein Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 244000141359 Malus pumila Species 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 208000031662 Noncommunicable disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- FTNIPWXXIGNQQF-UHFFFAOYSA-N UNPD130147 Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(OC4C(OC(O)C(O)C4O)CO)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O FTNIPWXXIGNQQF-UHFFFAOYSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 108010069085 allergen Hev b 5 Proteins 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- YETHWGOYCQLNKG-FHERGOJNSA-N alpha-D-Manp-(1->3)-[alpha-D-Manp-(1->6)]-alpha-D-Manp-(1->2)-alpha-D-Manp-(1->2)-D-Manp Chemical compound O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@H]1O[C@@H]1[C@@H](O[C@@H]2[C@H]([C@@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YETHWGOYCQLNKG-FHERGOJNSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000069 breast epithelial cell Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 108010037536 heparanase Proteins 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- WKMZPSWMEXVKKG-XITFREQTSA-N hevein Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CS)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CS)C(=O)NCC(=O)OC(=O)CC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)[C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O)CC1=CNC2=CC=CC=C12 WKMZPSWMEXVKKG-XITFREQTSA-N 0.000 description 1
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 1
- 229940099552 hyaluronan Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000005246 left atrium Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000000713 mesentery Anatomy 0.000 description 1
- 238000003358 metastasis assay Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000007171 neuropathology Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 230000006610 nonapoptotic cell death Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 1
- 239000002644 phorbol ester Substances 0.000 description 1
- YXJYBPXSEKMEEJ-UHFFFAOYSA-N phosphoric acid;sulfuric acid Chemical compound OP(O)(O)=O.OS(O)(=O)=O YXJYBPXSEKMEEJ-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001480 pro-metastatic effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 108010038196 saccharide-binding proteins Proteins 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08C—TREATMENT OR CHEMICAL MODIFICATION OF RUBBERS
- C08C1/00—Treatment of rubber latex
- C08C1/02—Chemical or physical treatment of rubber latex before or during concentration
- C08C1/04—Purifying; Deproteinising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Definitions
- the present invention relates generally to the field of cancer including tumor therapy. More particularly, the present invention relates to the prevention and treatment of cancers and cancer metastasis by using an extract of Hevea latex that is rich in low-molecular weight carbohydrates. The present invention also relates to pharmaceutical compositions for use in treating cancers, and to anti-cancer functional food compositions.
- cancers as a group is a major noncommunicable disease among the top four: cardiovascular disease, cancers, diabetes, and chronic lung diseases.
- cardiovascular disease cardiovascular disease
- cancers diabetes
- chronic lung diseases The American Cancer Society reported that, in 2012, the number of diagnosed new cancer cases worldwide was 14.1 million, with 8.2 million deaths. It has been predicted that by 2030 the number of new cancer cases may reach 21.7 million, with 13 million deaths (IARC. 2012. Global Cancer Facts & Figures, 3rd edition, produced by the American Cancer Society in partnership with the International Agency for Research on Cancer).
- cancer has been found to be closely related to biosignaling pathways that control the proliferation and destruction of body cells.
- Chemical agents that manipulate such pathways may be useful as anti-cancer agents.
- Small molecule targeted therapy drugs are generally inhibitors of catalytic or binding sites on mutated, overexpressed, or otherwise critical proteins within the cancer cells but only work for certain types of cancers.
- Other modern anti-cancer agents may work by acting as signals to stimulate the immune system of the patients.
- Many natural product-based anti-cancer treatments and medications are known in the prior arts. These active therapeutic agents range from small biomolecules to large macromolecules.
- Anti-cancer compounds An example of small anti-cancer biomolecules found in plant extracts, as disclosed in US patents number 6,432,452 (Anti-cancer compounds), is the angeloyl- substituted ingenane, a macrocyclic diterpene which competitively blocks the carcinogenic effects of phorbol ester, itself another macrocyclic diterpene.
- peptide allergens in Hevea has been used in pharmaceutical preparations to induce immune response in the treatment of diseases including cancer.
- PCT/EP2003/01 1190 Modular antigen transporter molecules for modulating immune reactions, associated constructs, methods and uses thereof
- PCT/EP2013/000291 Purge-based antigen transporter molecules for modulating immune reactions, associated constructs, methods and uses thereof
- EP2012/000418 Non- charged nucleic acid comprising complexes for immunostimulation
- EP2012/000420 Pulmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
- biochemical anti-cancer agents with molecular weight of a few kD, as shown in European Patent publication number 0 589 074 (Carbohydrate complexes for destruction of resistant cancer cells).
- Such anticancer effect may result from a combination of direct cytotoxicity, enhancement of chemotherapeutic agents' efficacy, and blockage of carcinogenesis.
- the antiproliferative effects have been shown for different types of human cancer, including ovarian cancer, colon cancer, prostate cancer (Khasraw, M., N. Pavlakis, S. McCowatt, C. Underhill, S. Begbie, P. de Souza, A. Boyce, F. Parnis, V. Lim, R. Harvie, and G. Marx. 2010.
- Annals of Oncology 21:1302- 1307), and astroglioma (Camby, I., C. Decaestecker, L. Gordower, R. DeDecker, Y. Kacem, A. Lemmers, H.C. Siebert, N.V. Bovin, P. Wesseling, A. Danguy, I. Salmon, H.J. Gabius, R. Kiss. 2001.
- the inventor surprisingly found that a more economically advantageous raw material for an anti-cancer extract is the serum that is obtained when acidified Hevea latex is calendered. It was also surprisingly found that this starting material, in conjunction with the extraction method disclosed herein, produces more uniform and reproducible products compared to other methods. Although it is highly unlikely that the chemical composition of the Hevea extract according to the present invention is the same as that of the so-called "low- molecular weight" carbohydrates cited in the prior arts due to differences both in the starting materials and in the extraction processes and conditions, the Hevea extract according to the present invention has been found to be active against cancer. Additionally, a relatively safe alcohol, such as ethanol, is used in the final precipitation step according to the present invention to eliminate any long-term health problems.
- a relatively safe alcohol such as ethanol
- HepG2 hepatocellular carcinoma cell line
- This serum can serve as an inexpensive source of starting material for biomolecules of high added values, especially those with therapeutic properties.
- the present invention utilizes this serum as the starting material for preparing a mixture of low-molecular weight carbohydrates.
- the Hevea latex serum comprises many other biomolecules, including allergenic proteins such as Hev bl, Hev b2, Hev b4, Hev b5, and Hev b6.02.
- allergenic proteins such as Hev bl, Hev b2, Hev b4, Hev b5, and Hev b6.02.
- Safety in this case comprises the absence of acute, sub-acute, and chronic toxicities as determined by relevant protocols.
- the invention herein described is directed to provide an extract of Hevea latex that is rich in low-molecular weight carbohydrates and having anti-cancer activity.
- One aspect of the disclosed invention is directed towards a method for preparing an extract of Hevea latex comprising the steps of: obtaining the serum released when acidified Hevea latex is calendered; optionally removing debris and micro-organisms from the serum; removing proteins; removing quebrachitol and small polar molecules; optionally dissolving the remaining solid powder in water; further removing proteins by treatment with acid; optionally neutralizing the excess acid; precipitating with solvent; collecting the precipitate; and optionally freeze drying the precipitate. Debris and micro-organisms are removed by technique comprising filtration.
- Proteins are removed by biochemical techniques comprising ultrafiltration and/or spray drying. Quebrachitol and small polar molecules are removed by extracting with a solvent such as methanol and collection of the remaining undissolved solid powder. Any leftover proteins are further removed by treatment with acid such as trichloroacetic acid. The remaining mixture is optionally adjusted to neutral pH and the final product is separated by precipitating with a cold organic solvent such as ethanol. The precipitate is collected by centrifugation and optionally freeze dried.
- Another aspect of the invention is directed towards a method for treating or preventing cancer growth and/or metastasis in a subject comprising administering to the subject an extract of Hevea latex, which is prepared by the process according to the present invention, in an effective amount to induce death of the cancer cells.
- a method for inhibiting tumor cell proliferation in a patient comprises administering to the patient Hevea latex extract according to the present invention in an effective amount to achieve a favorable change in one or more of the following markers: decreasing CD31 endothelial cell marker; decreasing VEGF angiogenic marker; decreasing COX-2 inflammatory marker; decreasing EGFR proliferation marker; increasing apoptosis of cancer cells; and decreasing galectin-3 metastasis marker.
- compositions comprising an extract of Hevea latex according to the present invention and one or more pharmaceutically acceptable substances.
- composition comprising an extract of Hevea latex according to the present invention and one or more edible ingredients.
- Figure 1 is a flow diagram that illustrates the origin of the raw material, Hevea latex serum.
- Figure 2 is a flow diagram that illustrates the steps in preparing an extract from Hevea latex serum according to the present invention.
- FIG. 3 is a flow diagram that illustrates the best mode embodiment of the invention.
- Figure 4 is a Fourier transform infrared (FT-IR) spectrum that illustrates a possible composition of the extract from Hevea latex according to the best mode embodiment of the invention.
- Figure 5 is the liquid chromatography - mass spectrometry (LC-MS) molecular mass profile of the extract of Hevea latex according to the best mode embodiment of the invention.
- FT-IR Fourier transform infrared
- LC-MS liquid chromatography - mass spectrometry
- Figure 8 illustrates how the dorsal skin fold chamber is surgically attached to a nude mouse in order to visualize angiogenesis.
- the diameter of the dorsal skin fold chamber is approximately 7 millimeter.
- Figure 9 illustrates the suppression of angiogenesis in nude mice with cancer implant in the dorsal skin fold chamber.
- the mouse was first anaesthesized.
- a fluorescein isothiocyanate-dextran (FITC-dextran) solution was then transfused into a jugular vein in order to label the blood vessels.
- the dorsal skin fold chamber, along with the skin with a cancer implant, was surgically removed and observed using a technique called "intravital confocal fluorescence video microscopy.”
- Left No cancer control.
- Figure 14 illustrates the increase in apoptosis in nude mice with cancer implant by daily oral gavage of 60 mg Hevea latex extract per kg body weight compared to controls which received water.
- TdT terminal deoxynucleotidyl transferase
- dUTP deoxyuridine triphosphate nucleotide
- TUNEL nick end labelling
- the well-known process for preparing Hevea serum starts with fresh latex 101 that is collected from rubber trees.
- An acid usually formic acid, is added to coagulate the latex.
- the coagulation with acid 102 converts the rubber isoprene polymer particles in the latex into coagula that start to separate from the liquid.
- This separation is expedited by squeeze milling, or calendering 103, that produces solid rubber, sheet rubber 104, as an output.
- the liquid released from this squeeze milling step is called the Hevea latex serum 105.
- the process according to the present invention uses this serum 105 as the starting material.
- the present invention provides a method for preparing an extract of Hevea latex.
- the method according to the invention comprises the steps of: obtaining the serum 205 released when acidified Hevea latex is calendered (This serum is identical to Hevea latex serum 105 in Figure 1.); optionally removing debris and micro-organisms 206; removing proteins 207; removing quebrachitol and small polar molecules 208; optionally dissolving the remaining solid powder in water 209; further removing proteins by treatment with acid 210; optionally neutralizing the excess acid 211; precipitating with solvent 212; collecting the precipitate 213; and optionally freeze drying the precipitate 214, to produce the Hevea latex extract 215.
- Steps 206-214, inclusive comprise conventional biochemical and biophysical techniques that are separately known to persons skilled in the art.
- steps 207, 208, and 210 do not need to be practiced in this particular sequence. Persons skilled in the art should be able to rearrange, substitute, and alter the details of these three steps. The best mode for carrying out the invention, nevertheless, will illustrate that arranging steps 207, 208, and 210 in this particular sequence has a practical and logistical advantage when the method is practiced.
- Step 206 is optionally needed if the latex serum is contaminated by debris and microorganisms such as bacteria, which depends on how clean the Hevea latex has been treated.
- One example of the removal technique is filtration through a filter with pore size small enough to exclude debris and micro-organisms, typically smaller than 0.5 micrometer and preferably 0.2 micrometer. Although smaller pore sizes can exclude even finer debris and particles, the filtration process gets slower as the pore size gets smaller. Since the inventor did not find any negative effect from possible contaminations of ultra-fine debris and nanoparticles, 0.2 micrometer filter pore size seems to be the best trade-off.
- Step 207 comprises removal of proteins, especially protein allergens that are naturally found in Hevea latex.
- This step comprises a combination of biochemical techniques such as enzymatic digestion, ultrafiltration, and spray drying at elevated temperatures.
- An example of step 207 is to destroy proteins by any commercial proteolytic enzyme that is cost- effective and retains its biological activity in the environment of the Hevea latex serum.
- Another example of step 207 is to filter the liquid through an ultrafiltration membrane with a cutoff molecular mass of at least 3 kD and preferably 10 kD.
- Another example of step 207 is to spray dry the liquid at a temperature above 60 degree Celsius, preferably above 100 degree Celsius and most preferably between 100 and 120 degree Celsius. In case ultrafiltration and spray drying are used in tandem, any protein that gets through the ultrafiltration membrane should then be denatured and deprived of its biological activity by the high temperature spray drying.
- Step 208 comprises the removal of quebrachitol and small polar molecules from the serum.
- the importance of this step will be apparent when the Hevea latex extract according to the present invention is combined with one or more pharmaceutically acceptable substances in order to form a composition to be used as anti-cancer medication.
- the importance will also be apparent when the Hevea latex extract is combined with one or more edible ingredients in order to form a composition to be used as anti-cancer functional food.
- an effective amount of the medication or the functional food has to be consumed by the cancer patient.
- Compliance of the patient depends, inter alia, on the lack of undesirable side effect such as diarrhoea that is known to be caused by quebrachitol.
- Step 210 comprises further removal of proteins by precipitating with acid in order to ensure more complete protein removal, especially small proteins and peptides that might have survived step 207.
- An example of step 210 is precipitation with 1 to 50 per cent, preferably from 2 to 10 per cent, and most preferably between 2 and 3 per cent of trichloroacetic acid at temperature above 4 degree Celsius, preferably between 16 and 30 degree Celsius, and most preferably between 20 and 25 degree Celsius.
- the time it takes to precipitate out proteins depends, inter alia, on the concentration of the acid used and the temperature at which the precipitation takes place. Practically, the precipitation is visible to the naked eyes in about 0.1 minute (almost immediately) after the acid is added.
- Step 209 serves as a transition from step 208 to step 210.
- the solid powder that remains undissolved from step 208 is optionally dissolved in a small volume of water in order to aid the precipitation reaction in step 210.
- Steps 212 and 213 involve separation of the final product, which is devoid of proteins but rich in low-molecular weight carbohydrates, for example, by precipitation at low temperature with a suitable mixture of solvents such as ethanol and water.
- concentration of ethanol should be at least 70 per cent, preferably 100 per cent.
- Precipitation is carried out below 4 degree Celsius, preferably below -10 degree Celsius, and most preferably at -20 degree Celsius. Although precipitation is visible in about 5 minutes, it is recommended to allow ample time of 24 hours for a maximum precipitation.
- Collection of the final product may be achieved, for example, by at least 3,000 x g centrifugation for at least 5 minutes, preferably for 10 minutes. This precipitate is optionally freeze dried in step 214.
- the final product is the anti-cancer Hevea latex extract 215. If the extract is to be used right away, step 214 can be omitted.
- the method according to the present invention automatically enriches the latex extract with low-molecular weight carbohydrates without any explicit digestion step for two reasons.
- utilizing the serum 105, or equivalently 205, as raw material carries an inherent advantage of having carbohydrates that are originally present in the fresh Hevea latex 101 at least partially digested down to low- molecular weight carbohydrates in the acid coagulation step 102.
- the raw material used according to the present invention is already partially enriched in low- molecular weight carbohydrates.
- spray drying at an elevated temperature is used in the removal of protein step 207, the high temperature may contribute to breaking down some of the carbohydrates.
- the further removal of proteins by acid step 210 also helps to further hydrolyze any remaining carbohydrates into low-molecular weight carbohydrates.
- the time, temperature, and concentrations of reactants in each step must be controlled to ensure that the resulting extract 215 has a uniform and reproducible composition of low-molecular weight carbohydrates.
- the inventor has unexpectedly discovered that the method according to the best mode of the present invention gives the most uniform and best reproducibility in the composition of low molecular weight carbohydrates compared to other methods and embodiments. Again, it should be emphasized that the exact chemical nature of the low molecular weight carbohydrates according to the present invention is expected to be different from that of the so-called "low molecular weight" carbohydrates according to the prior arts, due to differences in the starting materials and in the extraction processes.
- Another advantage of the present invention is that, if spray drying at elevated temperature is utilized in the removal of protein step 207, any protein that is not physically removed in other steps will be denatured by heat and will lose its three-dimensional disposition of any possible antigenic epitope, rendering such protein non-allergenic.
- the best mode of carrying out the invention known at present is to use the method according to the Example below.
- Figure 3 serves to illustrate the best mode for carrying out the present invention.
- the best mode starts with obtaining the serum 305, which is released when acidified Hevea latex is calendered.
- the starting material 305 refer to the same latex serum 105 in Figure 1 and 205 in Figure 2.
- the final product 315 corresponds to the same product 215 in Figure 2.
- the filtration step 306 to remove debris and micro-organisms comprises filtration through a membrane with a pore diameter of 0.2 micrometer.
- the protein removal step 307 consists of ultrafiltration 316 through an ultrafiltration membrane with a cutoff molecular weight of 10 kD, followed by spray drying 317 at a temperature of 1 10 degree Celsius. Since ultrafiltration and spray drying are used in tandem, any protein that passes through the ultrafiltration membrane would then be denatured and deprived of its biological activity by the high temperature spray drying. This allows the use of ultrafiltration membrane with 10 kD cutoff molecular weight instead of 3 kD membrane, which is more expensive and produces slower ultrafiltration rate at the same pressure.
- any allergenic protein with molecular weight between 3 and 10 kD such as Hev b 6.02, which is a 4.72 kD polypeptide, which would pass through the 10 kD ultrafiltration membrane, would be deactivated by the high temperature in the spray drying process.
- the inventor has found that the spray drying should be performed at a temperature above 60 degree Celsius, preferably above 100 degree Celsius, and most preferably between 100 and 120 degree Celsius. Although higher spray dry temperatures may allow for faster drying, better protein denaturation, and possibly production of more short-chain carbohydrates, they present a risk of altering the sugar structure and the color of the product.
- the solid powder from the spray drying step 317 is then extracted 308 with a mixture of at least 70 per cent aqueous methanol, which is a relatively polar organic solvent that is also relatively inexpensive.
- the extraction is performed with absolute methanol at 1 :6 weight to volume ratio, i.e. 1 weight of the solid powder to 6 volume of solvent.
- the extraction is repeated twice more, again with methanol, at 1 :4 weight to volume ratio, for a total of three times.
- the remaining solid powder from the methanol extraction step 308 is dissolved in distilled water 309 at 1 :8 weight to volume ratio.
- Trichloroacetic acid is added in step 310 to achieve a final concentration of 2.5 per cent.
- the mixture is stirred for 24 hours at 25 degree Celsius.
- the precipitate is removed and discarded by 3,000 x g centrifugation for 5 minutes. Although the function of this precipitation step is to remove proteins, macromolecules including nucleic acid polymers, if present, would be removed as well.
- the supernatant from step 310 is then neutralized with sodium hydroxide 311 and then precipitated 312 with absolute ethanol.
- the temperature is kept at -20 degree Celsius.
- the precipitate is collected in step 313 at 3,000 x g centrifugation for 5 minutes.
- the precipitate is freeze dried in step 314 to produce the Hevea latex extract 315 that can be kept in a deep freezer for an extended period, typically several months.
- the logistics for proteins and small polar molecules removal starts with ultrafiltration 316 followed by spray drying 317 then methanol extraction 308 and finally treatment with trichloroacetic acid 310.
- This sequence ensures that the large volume of the raw material 305 that has been cleared of debris and micro- organisms by filtration 306 is reduced by spray drying 317 to solid powder so as to facilitate the steps of methanol extraction 308 and treatment with trichloroacetic acid 310.
- the sequence of steps disclosed in this best mode example is the most practical and effective way to prepare the Hevea latex extract according to the present invention known to the inventor at the time of filing the PCT application.
- the yield of the best mode embodiment is approximately 0.17 per cent (weight of latex extract to serum volume).
- 9,650 litre of fresh Hevea latex 101 released 4,147 litre of serum 105 after calendering 103, which served as the raw material 305 to the best mode embodiment of the present invention.
- the volume was reduced to 3,869 litres.
- the spray drying step 317 gave 102 kg of solid powder.
- the ethanol precipitation step 312 and the freeze drying step 314 gave 7 kg of the final product 315.
- Figure 4 shows a Fourier transform infrared (FT-IR) spectrum that illustrates a possible composition of the extract from Hevea latex.
- the horizontal axis represents the wavenumber from 4000 to well under 1000 cm “1 .
- the vertical axis represents per cent transmittance.
- Major absorption peaks comprise 3392.75, 1619.95, 1418.21, 847.55, and 526.14 cm “ '.
- the 1081.41 cm “1 absorption peak cannot be further resolved, it is fairly close to the theoretical 1078.21 cm “1 and 1079.77 cm “1 absorption peaks that result from stretching of the beta 1,3 glycosidic bond of beta-l,3-glycan.
- Figure 5 shows the liquid chromatography-mass spectrometry (LC-MS) molecular mass profile of the extract of Hevea latex.
- the horizontal axis of this particular histogram has been prepared to represent the mass of the molecular fragments from below 2000 to 6000 Dalton.
- the vertical axis represents the per cent of a particular fragment in the sample.
- the graph illustrates the size distribution of the molecular mass of the components in the extract, with centers around 3712.1 Dalton. Representative molecular masses around the center peak are labeled both above (3713.6, 3744.8, 3759.1, 3800.1, and 3824.6 Dalton) and below (3705.6, 3651.0, 3635.8, and 3554.5 Dalton) the peak.
- the center molecular weight would correspond to a polymer of about 20 saccharide residues. From Figures 4 and 5, and the fact that the method according to the present invention is designed to remove proteins, nucleic acids, and other polar molecules, it is likely that the Hevea extract 315 contains low-molecular weight carbohydrates of about 20 saccharide residues.
- the extract from Hevea latex according to the present invention has been tested for acute toxicity, 6-week sub-acute toxicity, and 9-month chronic toxicity.
- Hevea latex extract When 6 male rats were fed daily with 1 gram Hevea latex extract per kg body weight for 6 weeks and compared to 6 male rat control group, no sub-acute toxicity was found with regard to food appetite, body weight, liver function, kidney function, white blood cell count, platelet count, hemoglobin and hematocrit, blood sugar level, blood lipids level, fatty deposit under the skin and in internal organs such as liver, and the size of internal organs (liver, kidney, heart, lung, pancreas, adrenal gland, testis, prostate gland, and seminal vesicle). Furthermore, the Hevea latex extract seems to induce nitric oxide release from vascular lining that results in better compliance of blood vessels and restoration of endothelium dysfunction.
- rats in the experimental satellite group were fed daily with 1 gram Hevea latex extract per kg body weight for 9 months followed by distilled water for another 28 days while rats in the control satellite group were fed with distilled water for the whole duration of 9 months plus 28 days.
- No abnormality was detected by gross necropsy with respect to body weight, the weight of internal organs (liver, kidney, adrenal gland, left atrium, right atrium, ventricles, spleen, lung, testis, epididymis, prostate gland, and seminal vesicle), subdermal fatty deposit, and fatty deposit in internal organs (epididymis, prostate, mesentery, and retroperitoneal organs).
- WBC white blood cell count
- HCT hemoglobin concentration
- MCV mean corpuscular volume
- MHC mean corpuscular hemoglobin concentration
- LYMPH per cent lymphocytes
- Pit platelet concentration
- the Hevea extract according to the present invention was shown to be endowed with (1) anti-cancer activity and (2) anti-metastasis activity. Owing to these activities, the present invention is applicable to industries comprising (1) the pharmaceutical industry and (2) the food industry.
- mice Six to eight weeks old male BALB/C nude mice (athymic mice), weighing between 20 and 25 grams, were injected with 10 6 CaSki cells (cervical cancer cells of human papillomaviruses type 16 origin) and allowed to live normally for approximately one month until the tumor volume was approximately 100 to 120 cubic millimeter, as calculated form linear measurements using a vernier calliper shown in Figure 6.
- Mice in the experimental group received daily oral gavage of 60 milligram Hevea latex extract 315 per kg body weight for 28 days while mice in the control group received water.
- Figure 7 shows the time course of relative tumor volume in the two groups of mice. While the volume of tumor in the control group increased about 7 times in 4 weeks, the volume of tumor in the group that received Hevea latex extract 315 stayed roughly unchanged. (b) effect on angiogenesis of tumor planted in nude mice
- mice Six to eight weeks old male BALB/C nude mice, weighing between 20 and 25 grams, were fitted with 7 millimetre dorsal skin fold chambers as shown in Figure 8 and implanted into the chamber with 2 x 10 6 CaSki cells.
- Mice in the experimental group received daily oral gavage of 60 milligram Hevea latex extract per kg body weight for 14 days while mice in the control group received water. On the 14th day, the animals were anaesthetised with 50 mg/kg sodium pentobarbital. Blood plasma was labelled with fluorescein isothiocyanate- dextran (FITC-dextran). The dorsal skin fold chambers were carefully removed along with the skin.
- FITC-dextran fluorescein isothiocyanate- dextran
- metastasis of melanoma cells injected into nude mice tail veins was assessed at two weeks after injection.
- metastatic melanoma colonies can be seen by naked eyes as black spots against the reddish lung background.
- metastasized melanoma cells can be located by the immunohistochemistry staining assay of galectin-3, a metastasis marker.
- the anti-metastatic activity of the Hevea latex extract according to the present invention was shown in nude mice that had been injected into their tail veins with 10 5 melanoma B16-F1 cells.
- Figure 15 shows the result of this experiment.
- the number of metastasized melanoma black spots are significantly fewer than in the group which received water instead of the Hevea latex extract (top row).
- the invention is applicable to the pharmaceutical industry since the Hevea extract according to the present invention is useful as an ingredient of pharmaceutical compositions for treating cancers.
- the acute, sub-acute, and chronic toxicological studies in rats, as described in the above section, have shown that the Hevea latex extract according to the present invention is non-toxic.
- a medical composition for treating cancer can be made comprising an extract of Hevea latex according to the present invention and one or more pharmaceutically acceptable substances selected from the group consisting of additive, binder, carrier, diluent, excipient, filler, lubricant, solvent, and stabilizer.
- the extract according to the present invention Owing to the Hevea latex extract's anti-cancer and anti-metastatic activities in nude mice, it follows that we should expect the extract according to the present invention to function as an anti-cancer and anti-metastatic agent in a broad range of animals, including humans, and in a broad range of cancers, such as AIDS related cancer, acoustic neoma, adenocystic carcinoma, adrenocortical cancer, agnogenic myeloid metaplasia, alopecia, alveolar soft- part sarcoma, angiosarcoma, aplastic anaemia, astrocytoma, ataxia-telangiectasia, basal cell carcinoma (bcc), brain stem glioma, carcinoid cancers, childhood cancer, childhood soft tissue sarcoma, chondrosarcoma, choriocarcinoma, colorectal cancers, cutaneous T-Cell lymphoma,
- the anti-cancer and anti-metastasis activities of the Hevea latex extract according to the present invention should be applicable to cancers of different organs and organ systems, such as the anus, bladder, bone, bowel, brain, breast, central nervous system, cervix, colon, endocrine gland, ear, endothelial cells, esophagus, eye, gall bladder, head, intestine, kidney, larynx, leucocytes, lip, liver, lung, mouth, nasal cavity, neck, nose, oral cavity, ovary, pancreas, pharynx, pituitary, prostate, rectum, salivary gland, skin, spinal cord, stomach, testicles, thymus, thyroid, urethra, urinary system, uterus, vagina, and vulva.
- organs and organ systems such as the anus, bladder, bone, bowel, brain, breast, central nervous system, cervix, colon, endocrine gland, ear, endothelial cells,
- Hevea latex extract In case the Hevea latex extract is to be used as an anti-cancer/ anti-metastasis agent, it may be prepared into the forms of aqueous solution, tablet, lozenge, powder, aqueous or oily suspension, emulsion, syrup, elixir.
- the route of administration may be enteral, intramuscular, intravenous, nasal, oral, parenteral, rectal, subcutaneous, sublingual, sublabial, transdermal and transmucosal.
- Hevea latex extract may be combined with a therapeutically effective amount or one or more chemotherapeutic agents such as alkylating agent, antimetabolite, anti-tumor antibiotic, kinase inhibitor, aromatase inhibitor, mitotic inhibitor, steriod hormone, and topoisomerase inhibitor.
- chemotherapeutic agents such as alkylating agent, antimetabolite, anti-tumor antibiotic, kinase inhibitor, aromatase inhibitor, mitotic inhibitor, steriod hormone, and topoisomerase inhibitor.
- an extract of Hevea latex according to the present invention may be mixed with one or more edible ingredients selected from the group consisting of acid, acidity regulator, additive, anti caking agent, antifoaming agent, antioxidant, baking agent, binder, carrier, color retention agent, diluent, emulsifier, excipient, filler, flavour, flavour enhancer, flour treatment agent, food colouring agent, glazing agent, humectant, lubricant, preservative, solvent, stabilizer, sweetener, and thickener.
- edible ingredients selected from the group consisting of acid, acidity regulator, additive, anti caking agent, antifoaming agent, antioxidant, baking agent, binder, carrier, color retention agent, diluent, emulsifier, excipient, filler, flavour, flavour enhancer, flour treatment agent, food colouring agent, glazing agent, humectant, lubricant, preservative, solvent, stabilizer, sweetener, and thickener.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/TH2016/000075 WO2018044242A1 (en) | 2016-09-02 | 2016-09-02 | Method for preparing an extract of hevea latex and composition thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3510052A1 true EP3510052A1 (en) | 2019-07-17 |
EP3510052A4 EP3510052A4 (en) | 2020-06-17 |
Family
ID=61309153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16915342.6A Pending EP3510052A4 (en) | 2016-09-02 | 2016-09-02 | Method for preparing an extract of hevea latex and composition thereof |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP3510052A4 (en) |
CN (1) | CN110023342B (en) |
MY (1) | MY197240A (en) |
WO (1) | WO2018044242A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023055307A1 (en) * | 2021-09-29 | 2023-04-06 | Master Labs Incorporation Company Limited | Process for extracting hevea latex polysaccharides from effluent of the rubber manufacturing industry, polysaccharide extract, composition and use thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1758616A (en) * | 1925-12-02 | 1930-05-13 | Naugatuck Chem Co | Method for recovering quebrachitol from rubber latex serum |
JPS61293201A (en) * | 1985-06-22 | 1986-12-24 | Yokohama Rubber Co Ltd:The | Powdered nonrubber component obtained from serum of natural rubber latex and production thereof |
JPH0291035A (en) * | 1988-07-06 | 1990-03-30 | Yokohama Rubber Co Ltd:The | Collection of l-quebrachitol in natural rubber serum |
EP0589074B1 (en) | 1992-09-22 | 2001-11-21 | Takeo Dr. Takayanagi | Carbohydrate complexes for destruction of resistant cancer cells |
US5834442A (en) | 1994-07-07 | 1998-11-10 | Barbara Ann Karmanos Cancer Institute | Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin |
AUPO864097A0 (en) | 1997-08-19 | 1997-09-11 | Peplin Pty Ltd | Anti-cancer compounds |
MY139558A (en) * | 2003-02-28 | 2009-10-30 | Malaysian Rubber Board | A protein |
EP2926818A1 (en) | 2004-03-26 | 2015-10-07 | La Jolla Pharmaceutical Company | Modified pectins, compositions and methods related thereto |
MY153171A (en) * | 2006-12-21 | 2015-01-29 | Thailand Ct Of Excellence For Life Sciences | Skin whitening composition containing extracts derived from natural rubber latex |
WO2009156164A1 (en) * | 2008-06-27 | 2009-12-30 | Akzo Nobel N.V. | Redispersible polymer powder |
CN102516041A (en) * | 2011-12-16 | 2012-06-27 | 云南省热带作物科学研究所 | Method for extracting quebrachitol from natural rubber whey |
-
2016
- 2016-09-02 CN CN201680090627.8A patent/CN110023342B/en active Active
- 2016-09-02 EP EP16915342.6A patent/EP3510052A4/en active Pending
- 2016-09-02 WO PCT/TH2016/000075 patent/WO2018044242A1/en active Search and Examination
- 2016-09-02 MY MYPI2019002474A patent/MY197240A/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2018044242A1 (en) | 2018-03-08 |
EP3510052A4 (en) | 2020-06-17 |
MY197240A (en) | 2023-06-07 |
CN110023342B (en) | 2022-01-11 |
CN110023342A (en) | 2019-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xiao et al. | Immune activities of polysaccharides isolated from Lycium barbarum L. What do we know so far? | |
KR100831408B1 (en) | Potent immunostimulants from microalgae | |
WO2005112967A2 (en) | Anticancer activity of chios mastic gum | |
JP2021176888A (en) | Therapeutic pharmaceutical composition comprising purple corn extract for prevention or treatment of skin disease | |
Kim et al. | Skin whitening and anti-corrugation activities of glycoprotein fractions from liquid extracts of boiled sea cucumber | |
JP2009500446A (en) | Pharmaceutical composition having an effect of preventing and treating liver diseases, comprising an extract of keyonomi | |
JP6251455B2 (en) | Rheumatoid arthritis inhibitor, rheumatoid arthritis preventive agent, rheumatoid arthritis therapeutic agent, and food for suppressing rheumatoid arthritis | |
KR102111372B1 (en) | Composition comprising an extract from sea cucumber for preventing and treating Bruch's membrane malfunction-related disease | |
WO2018044242A1 (en) | Method for preparing an extract of hevea latex and composition thereof | |
KR101559483B1 (en) | Neuroprotective composition comprising extracts or fractions of seaweed as an active ingredient | |
KR101092304B1 (en) | soybean extract of enhancing biosynthesis of hyaluronic acid and glycosaminoglycan | |
AU2015352042B2 (en) | Titled extracts of Cynara scolymus for use in the treatment of mesothelioma | |
WO2020000828A1 (en) | Gracilaria lemaneiformis polysaccharide having significant hypolipidemic activity and preparation method therefor and use thereof | |
KR101326870B1 (en) | Pharmaceutical composition for preventing or treating acute renal failure comprising herbal extract or fraction thereof as an active ingredient | |
KR102659740B1 (en) | Anti-cancer use of sea cucumber gonad extract or the compound derived from the same | |
KR101771897B1 (en) | Pharmaceutical composition for the treatment of cancers or inhibition of metastasis containing extract of chlorella sp. | |
KR101579820B1 (en) | Pharmaceutical compositions for the treatment of cancer metastasis or inhibition of metastasis containing Quassia undulata extracts as active fractions | |
JP2008208102A (en) | Intestinal tract immunoactivator and antiallergic agent | |
KR102324233B1 (en) | Novel use of Extract of Solani Nigri Herba | |
CN110522762B (en) | Biological polysaccharide for preventing and treating inflammation and application thereof | |
JP2020186215A (en) | Composition for improvement of menopause symptom | |
KR101862552B1 (en) | Pharmaceutical composition, health functional food and cosmetic composition | |
KR102119812B1 (en) | Composition for Preventing or Treating Uterine Myoma Comprising Rhus verniciflua Stokes Extract | |
Dhanalakshmi et al. | Preliminary phytochemical investigation of Hypnea valentiae with antigluconegenesis activity in goat eye | |
KR102063321B1 (en) | Composition for Preventing or Treating Uterine Myoma Comprising Orostachys japonicus Extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20190502 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20200515 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 36/47 20060101ALI20200511BHEP Ipc: C08C 2/02 20060101ALI20200511BHEP Ipc: A61P 35/00 20060101ALI20200511BHEP Ipc: C08C 1/04 20060101ALI20200511BHEP Ipc: C08C 1/02 20060101AFI20200511BHEP Ipc: C08L 7/02 20060101ALI20200511BHEP |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20240130 |
|
RAP3 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: PRINCE OF SONGKLA UNIVERSITY Owner name: THAILAND CENTER OF EXCELLENCE FOR LIFE SCIENCES |